Literature DB >> 11861332

Pharmacological characterization of the chemokine receptor, CCR5.

Anja Mueller1, Nasir G Mahmoud, Marc C Goedecke, Jane A McKeating, Philip G Strange.   

Abstract

1. We investigated the effects of a number of naturally occurring chemokines (MIP-1alpha, MIP-1beta, RANTES, MCP-2, MCP-3, MCP-4) on different processes linked to the chemokine receptor CCR5 in recombinant CHO cells expressing the receptor at different levels. 2. Internalization of CCR5 following chemokine treatment was studied and MIP-1alpha, MIP-1beta and RANTES (50 nM) were able to induce internalization (similar50%) of the receptor. Internalization due to MCP-2, MCP-3 and MCP-4 was less (similar20%). 3. Phosphorylation of CCR5 following chemokine treatment was studied and MIP-1alpha, MIP-1beta and RANTES (50 nM) were able to induce phosphorylation of CCR5 whereas the other chemokines did not induce CCR5 phosphorylation. 4. MIP-1alpha, MIP-1beta, RANTES and MCP-2 were able to stimulate [(35)S]-GTPgammaS binding, an index of receptor/G protein activation, whereas MCP-3 and MCP-4 had no effect in this assay. MCP-2 was a partial agonist (similar80%) compared to MIP-1alpha, MIP-1beta and RANTES, which gave similar maximal stimulations in this assay. 5. MIP-1alpha, MIP-1beta, RANTES, MCP-2 and MCP-4 were able to stimulate increases in intracellular calcium ions via activation of CCR5 whereas MCP-3 was without effect. 6. It is concluded that different chemokines interacting with CCR5 mediate different patterns of cellular responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861332      PMCID: PMC1573204          DOI: 10.1038/sj.bjp.0704540

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

Review 1.  G-protein-coupled receptors: turn-ons and turn-offs.

Authors:  C V Carman; J L Benovic
Journal:  Curr Opin Neurobiol       Date:  1998-06       Impact factor: 6.627

Review 2.  Chemokine receptors: keys to AIDS pathogenesis?

Authors:  D R Littman
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 3.  G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization.

Authors:  R J Lefkowitz
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

4.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.

Authors:  C C Bleul; L Wu; J A Hoxie; T A Springer; C R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 5.  Human chemokines: an update.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.

Authors:  G Alkhatib; M Locati; P E Kennedy; P M Murphy; E A Berger
Journal:  Virology       Date:  1997-08-04       Impact factor: 3.616

7.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells.

Authors:  B Gardner; D A Hall; P G Strange
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.

Authors:  M Mack; B Luckow; P J Nelson; J Cihak; G Simmons; P R Clapham; N Signoret; M Marsh; M Stangassinger; F Borlat; T N Wells; D Schlöndorff; A E Proudfoot
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

10.  HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication.

Authors:  A Amara; S L Gall; O Schwartz; J Salamero; M Montes; P Loetscher; M Baggiolini; J L Virelizier; F Arenzana-Seisdedos
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

View more
  14 in total

1.  Characterization of the endokinins: human tachykinins with cardiovascular activity.

Authors:  Nigel M Page; Nicola J Bell; Sheila M Gardiner; Isaac T Manyonda; Kerensa J Brayley; Philip G Strange; Philip J Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

Review 2.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Authors:  Ivana Massud; Wutyi Aung; Amy Martin; Shanon Bachman; James Mitchell; Rachael Aubert; Theodros Solomon Tsegaye; Ellen Kersh; Chou-Pong Pau; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

4.  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Authors:  Patrick Dorr; Mike Westby; Susan Dobbs; Paul Griffin; Becky Irvine; Malcolm Macartney; Julie Mori; Graham Rickett; Caroline Smith-Burchnell; Carolyn Napier; Rob Webster; Duncan Armour; David Price; Blanda Stammen; Anthony Wood; Manos Perros
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.

Authors:  E C Halvorsen; M J Hamilton; A Young; B J Wadsworth; N E LePard; H N Lee; N Firmino; J L Collier; K L Bennewith
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

6.  Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity.

Authors:  Kathryn E Medders; Natalia E Sejbuk; Ricky Maung; Maya K Desai; Marcus Kaul
Journal:  J Immunol       Date:  2010-09-20       Impact factor: 5.422

7.  Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.

Authors:  Hirotomo Nakata; Michael Kruhlak; Wakako Kamata; Hiromi Ogata-Aoki; Jianfeng Li; Kenji Maeda; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antivir Ther       Date:  2010

8.  Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).

Authors:  Irene Chernova; Jian-Ping Lai; Haiying Li; Lynnae Schwartz; Florin Tuluc; Helen M Korchak; Steven D Douglas; Laurie E Kilpatrick
Journal:  J Leukoc Biol       Date:  2008-10-03       Impact factor: 4.962

9.  CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo.

Authors:  Li-Chung Tsao; Haitao Guo; Jerry Jeffrey; James A Hoxie; Lishan Su
Journal:  Retrovirology       Date:  2016-03-29       Impact factor: 4.602

10.  The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.

Authors:  Qingwen Jin; Hong Chen; Xingxia Wang; Liandong Zhao; Qingchen Xu; Huijuan Wang; Guanyu Li; Xiaofan Yang; Hongming Ma; Haoquan Wu; Xiaohui Ji
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.